t e c h n i c a l r e p o r t s Most human cancers, including myeloma, are preceded by a precursor state. There is an unmet need for in vivo models to study the interaction of human preneoplastic cells in the bone marrow microenvironment with non-malignant cells. Here, we genetically humanized mice to permit the growth of primary human preneoplastic and malignant plasma cells together with non-malignant cells in vivo. Growth was largely restricted to the bone marrow, mirroring the pattern in patients with myeloma. Xenografts captured the genomic complexity of parental tumors and revealed additional somatic changes. Moreover, xenografts from patients with preneoplastic gammopathy showed progressive growth, suggesting that the clinical stability of these lesions may in part be due to growth controls extrinsic to tumor cells. These data demonstrate a new approach to investigate the entire spectrum of human plasma cell neoplasia and illustrate the utility of humanized models for understanding the functional diversity of human tumors.
Multiple myeloma (MM) is characterized by the growth of malignant plasma cells predominantly in the bone marrow, leading to lytic bone disease 1 . In nearly all cases, MM is preceded by clinically asymptomatic precursor states, termed monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic MM (AMM). Although several transgenic mouse models of plasma cell tumors have been described, these lack the known genetic drivers that characterize human MM and MGUS 2 . Hence, there is an unmet need for in vivo mouse models that would allow the growth and investigation of patient-specific primary human tumors (and particularly precursor states) 2 . Immune-deficient mice implanted with fetal human bone (SCID-hu) or synthetic bone scaffolds (SCID-synth-hu) have been used to study the growth of MM (though not MGUS) cells, but these have several limitations, including the limited availability of human fetal tissues in large parts of the world [2] [3] [4] . Major obstacles to facile growth of human cells in mice are the innate rejection pathways and the lack of interspecies cross-reactivity of certain cytokines and growth factors 5 . To overcome these obstacles, we recently developed humanized mice containing knock-in alleles that express the human versions of five genes important for innate immune cell development and hematopoiesis [5] [6] [7] . These mice (termed MIS (KI) TRG, for human M-CSF, IL-3, GM-CSF, thrombopoietin and SIRPα knock in) exhibit superior multilineage engraftment of human hematopoietic stem cells, including innate immune cells. We hypothesized that humanization of interleukin-6 (IL-6), a critical growth factor for human MM that lacks species cross-reactivity 8, 9 , would provide critical signals necessary for MM cell survival. Therefore, we modified MIS (KI) TRG mice with an additional knock-in allele that expresses human IL-6, to generate MIS (KI) TRG6 mice, and tested the ability of MM cells to grow in these mice.
RESULTS
Growth of human IL-6-dependent cells INA-6 is a human IL-6-dependent MM cell line commonly used for MM models in the context of the SCID-hu system 10 . We first analyzed the capacity of these cells to grow in Rag2 − Il2rg −− mice expressing either mouse or human IL-6. We initially verified the capacity of these mice to produce IL-6 following injection of lipopolysaccharide in vivo (Supplementary Fig. 1 ). Injection of INA-6 cells into the bones of mice expressing human IL-6 led to IL-6-dependent tumor growth, manifested as an increase in human sIL-6R in the circulation and bone destruction ( Supplementary Fig. 2a,b) , analogous to the growth of INA-6 cells described previously in SCID-hu mice 10 . INA-6 cells could also grow in mice expressing both human IL-6 and human SIRPα (the latter intended to help overcome phagocytosis of tumor cells by innate immune cells) with slightly improved kinetics as compared to mice expressing human IL-6 alone; however, this difference was not significant, which could be due to analysis of an insufficient number of mice ( Supplementary Fig. 2c ). Together, these data show that the presence of human IL-6, but not mouse IL-6, supports INA-6 growth in vivo, and demonstrate the feasibility of using human IL-6-expressing mice to study bone destruction by this MM cell line. t e c h n i c a l r e p o r t s
Growth of primary MM cells
We generated MIS (KI) TRG6 mice by introducing a human IL6 knock-in allele into MIS (KI) TRG mice. Although INA-6 cells were able to grow in Rag2 −− Il2rg −− SIRPα h/h IL-6 h/h mice, primary MM cells showed poorer growth in these mice than in MIS (KI) TRG6 mice ( Supplementary Fig. 2d ). Therefore, we subsequently used MIS (KI) TRG6 mice for studying the growth of primary MM cells in vivo (Fig. 1a) . Primary MM cells were isolated from bone marrow of patients with MM (see Supplementary Table 1 for patient characteristics). The growth of tumor cells was monitored by both flow cytometry of cells in the bone marrow and levels of human immunoglobulin light chains in the blood. Primary MM cells injected into bone of MIS (KI) TRG6 mice grew in the injected bone but not in the spleen ( Fig. 1b-d) . In contrast, non-malignant cells such as human T cells could be detected in the spleen. A detailed phenotypic analysis of xenografted tumors using mass cytometry revealed similarity to isolated primary tumor cells before implantation for several proteins, including immune checkpoint markers ( Fig. 1e) .
Some studies have suggested that a subset of tumor cells lacking expression of CD138 may be enriched in clonogenic potential 11 , whereas others have shown that purified CD138 + plasma cells are capable of tumor growth 3, 12, 13 . Our prior studies suggested plasticity between these compartments 14 . In the MIS (KI) TRG6 model, injection of purified CD138 + cells or a CD138-depleted cell population similarly led to the growth of CD138 + tumor cells in vivo, indicating that both compartments contain cells capable of repopulating tumors ( Fig. 2a,b) . Depletion of CD3 + T cells from bone marrow mononuclear cells (BMMNCs) before adoptive transfer was performed to reduce the risk of xenograft-versus-host disease (xeno-GVHD), and this depletion emerged as an effective strategy to allow the growth of tumor cells in vivo (Fig. 2b) . Residual non-tumor cells in the isolated primary MM bone marrow cells underwent expansion in vivo in this model, such that human non-malignant cells from the tumor microenvironment were able to grow in these mice (Fig. 2c) . In addition to T cells, the spectrum of non-malignant human cells present in the bone marrow in these mice included myeloid cells, natural killer cells and B cells ( Fig. 2c) . Tumor cells from primary bone xenografts were also capable of repopulation upon serial transplantation ( Fig. 2d) MIS (KI) TRG6 mice, and that both malignant and non-malignant human cells can grow in these mice.
Microenvironment-dependent growth of MM and precursor states
Prior xenograft models have primarily focused on patients with clinical MM; reliable models for human preneoplastic gammopathies have not been described 2 . Injection of CD3-depleted BMMNCs from patients with either MGUS or AMM into MIS (KI) TRG6 led to the growth of tumor cells in vivo (Fig. 3a,b) . As in the case of tumor cells from patients with early-stage MM, cells isolated from patients with MGUS or AMM grew primarily in the injected bone. In contrast, we observed an enhanced ability of tumor cells to grow in the contralateral bone when samples from patients with relapsed/refractory MM were injected ( Fig. 3a) . For the even more aggressive disease stage of plasma cell leukemia (PCL), extramedullary growth of tumor cells was also observed (Fig. 3a) . Interestingly, tumor cells from patients with MGUS or AMM grew progressively in these mice, such that tumor cells constituted a higher proportion of bone marrow cells in the injected bone than they did in the preimplantation sample (Fig. 3a) . The percentage of clonal plasma cells in xenografts from patients with preneoplastic gammopathy (n = 5) was higher than in the corresponding primary samples (mean 4.9% in primary samples versus 27.4% in xenograft samples, P = 0.06). Injection of MM tumor cells in implanted human fetal bone (the SCID-hu model) is commonly used to grow advanced MM 3 and the INA-6 MM cell line 10 , but the reliable growth of preneoplastic stages in this model has not been described. In a direct comparison of the ability of the MIS (KI) TRG6 and SCID-hu models to support the growth of tumors from three patients with precursor-state MM (MGUS/AMM), we found that MIS (KI) TRG6 mice were superior to SCID-hu mice in their ability to support tumor growth ( Fig. 4) . Growth of INA-6 cells was used as a positive control for SCID-hu mice (Supplementary Fig. 3) . Taken together, these data show that the growth of tumor cells in MIS (KI) TRG6 mice is largely restricted to bone marrow and that these mice can serve as hosts for the entire spectrum of plasma cell dyscrasias, from MGUS to PCL, and offer several advantages over existing models, particularly for the growth of precursor states.
Genomic diversity of xenografts
Tumor growth in some xenograft models does not reproduce the genomic diversity of the parental tumors 15, 16 . To test whether MM Fig. 4 for the sorting strategy 17 and Supplementary Table 2 for sequencing summary statistics).
Comparison of loss-of-heterozygosity (LOH) patterns revealed that the majority of LOH changes in parental tumors were also observed in cells isolated from xenografts; however, xenograft cells contained additional LOH changes (Fig. 5a) . Profiling of somatic copy number alterations (CNAs) also revealed a similar pattern of genomic gains and losses between parental and xenograft cells (Fig. 5b) . Interestingly, the patterns of LOH and CNAs were identical in individual mice transplanted with the same parental tumor cells, indicating that the new patterns of genomic change observed upon xenografting were likely already present in a minor subclone in the parental cells ( Fig. 5c,d) . Notably, these new genomic changes detected in the xenografts included genomic changes in chromosome 1 typically associated with high-risk MM 18 (Supplementary Fig. 5 ). Analysis of somatic non-synonymous variants (SNVs) revealed that the great majority of SNVs detected in the parental tumors were also identified in xenografts; however, xenografts also contained additional SNVs not initially detected in the parental samples, including some SNVs with known oncogenic potential (Fig. 6) . As an example, a xenograftemergent SNV in MAPK8IP3 was detected in the parental sample upon PCR genomic amplification, indicating that at least some of the new SNVs detected in xenografts were already present in the parental cells as minor subclones (Supplementary Fig. 6) . Therefore, tumors growing in xenografts not only recapitulate the genomic diversity of the parental tumor, but also reveal the presence of minor subclones capable of growth in the xenogeneic environment.
DISCUSSION
These data demonstrate that the use of advanced humanized mice allows modeling of the entire spectrum of human plasma cell tumors-including, for the first time to our knowledge, preneoplastic lesions-without the need for human fetal tissue. The ability to reliably grow primary tumor cells in vivo has clear implications for preclinical testing and personalized therapies. These studies also provide several insights into the biology of these tumors. An important strength of this model is that it supports the growth of both malignant and non-malignant cells from the primary tumor. The improved growth of non-malignant cells in this model, as compared to other models, is likely due to improved human hematopoiesis in MIS (KI) TRG-derived mice, which express species-specific growth factors 5, 6 . The interaction of MM cells with non-malignant cells in the bone marrow, including immune cells, can affect the growth and evolution of tumors 14, 19, 20 . It is therefore important that xenotransplantation models permit the growth of patient-derived non-malignant as well as malignant cells. This feature is also essential for the preclinical investigation of emerging immune-based therapies 21 . It is therefore of interest that the expression of immune checkpoint markers in human tumor cells in this model resembled that in the primary tumor. Xenotransplantation models should recapitulate the biology of primary tumors, not only in terms of their growth pattern but also in terms of their genetics. In contrast to prior studies in which xenografts exhibited marked fluctuation in clonal architecture 22 , MM tumors grown in MIS (KI) TRG6 mice reflected the entire genetic diversity of the primary tumors. Growth of early MM lesions was largely restricted to the bone marrow (the natural site of tumor), without involvement of spleen or lymphoid tissue. Only advanced lesions exhibited the capacity to seed and expand in the contralateral bone. Furthermore, the capacity of tumor cells to grow in the spleen and circulation was observed only when the primary tumors had a circulating component in affected individuals, in the case of plasma The ability to grow preneoplastic lesions in vivo is particularly important to enable study of the biology of malignant transformation. In affected individuals, the tumor mass in precursor states such as MGUS remains stable over prolonged periods before transformation to clinical MM. Whether the stability of the clonal mass in MGUS is due to features intrinsic to tumor cells or to growth control mediated by extrinsic elements is not known. It is notable that recent genome sequencing studies have shown that nearly all of the genomic changes and mutations found in MM can be observed in MGUS; moreover, in the small studies in which serial samples from affected individuals were sequenced, very few, if any, additional mutations were detected at disease progression 17, [24] [25] [26] . The finding that tumor cells from MGUS exhibit progressive growth in mice suggests the presence of active extrinsic restraints (such as immune surveillance or niche-derived signals) in preventing clinical malignancy in humans [27] [28] [29] [30] [31] . Extrinsic restraints may be particularly important in restraining the growth of minor subclones with potentially 'highrisk' genetic lesions, such as were detected in our study. Use of this humanized mouse model for the study of the biology of clonal plasma cell diseases and emerging therapeutic approaches, as well as for the clinical evaluation of affected patients, may help the understanding the functional diversity of human tumors and the development of personalized therapies.
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